Por Renan Filho · 2026-10-01**Lead**
The American kratom industry is sounding an urgent alarm: synthetic opioids, particularly those laced with fentanyl or other laboratory-made compounds, should never be referred to as 'kratom.' In a series of public statements and regulatory filings, industry leaders argue that the mislabeling—whether accidental or deliberate—fuels a dangerous misconception that could lead to fatal overdoses and undermine years of efforts to establish kratom as a safe, natural botanical. The warning comes amid a surge in reports of adulterated kratom products and a renewed push by federal agencies to classify the plant as a Schedule I substance alongside heroin and LSD.
**Contexto**
Kratom, derived from the leaves of the *Mitragyna speciosa* tree native to Southeast Asia, has been used for centuries as a mild stimulant and pain reliever. In the United States, an estimated 10 to 15 million people use kratom products, often to manage chronic pain, anxiety, or opioid withdrawal symptoms. The plant contains alkaloids—primarily mitragynine and 7-hydroxymitragynine—that interact with opioid receptors in the brain, but with a significantly lower risk of respiratory depression compared to classical opioids like morphine or fentanyl.
However, the unregulated nature of the kratom market has created a gray zone. The U.S. Food and Drug Administration (FDA) has repeatedly warned about contamination and adulteration, including cases where kratom powder was found to contain synthetic opioids such as fentanyl or U-47700. In 2023, the Centers for Disease Control and Prevention (CDC) linked several overdose deaths to kratom products that were later confirmed to be adulterated with synthetic opioids. These incidents have been seized upon by critics who argue that kratom itself is inherently dangerous, a claim the industry vehemently disputes.
The American Kratom Association (AKA), the leading trade group representing growers, processors, and retailers, has long advocated for federal regulation through the Kratom Consumer Protection Act (KCPA), which would establish quality standards and testing requirements. The AKA argues that the real threat is not the plant itself but the illegal addition of synthetic opioids by bad actors. By conflating the two, the industry says, regulators and the media risk stigmatizing a substance that many users credit with saving their lives from addiction.
**Analise**
The semantic battle over what constitutes 'kratom' has real-world consequences. When a news report states that 'kratom caused an overdose,' it often fails to distinguish between pure kratom and kratom that has been spiked with synthetic opioids. This conflation can lead to policy decisions based on flawed data. For example, the FDA’s 2022 risk assessment, which recommended scheduling kratom as a Schedule I substance, relied heavily on adverse event reports that included cases of adulterated products. Industry experts argue that such assessments are scientifically unsound because they do not isolate the effects of the plant itself.
Moreover, the mislabeling creates a public health hazard. Consumers who hear that 'kratom is dangerous' may be deterred from using a potentially safer alternative to prescription opioids or illicit street drugs. Conversely, those who seek kratom for therapeutic purposes may unknowingly purchase adulterated products if they rely on unverified vendors. The AKA has called for mandatory testing and labeling requirements that would clearly distinguish between pure kratom and any product containing synthetic additives.
The issue also intersects with the broader opioid crisis. As fentanyl continues to drive overdose deaths—accounting for over 70,000 fatalities in 2024 according to provisional CDC data—any substance that can be easily adulterated becomes a vector for harm. The kratom industry’s position is that it is being unfairly scapegoated. 'We are not asking for a free pass,' said an AKA spokesperson in a recent webinar. 'We are asking for honest science and honest language. A fentanyl-laced product is not kratom. It is poison.'
**Fontes**
- American Kratom Association (AKA) – public statements and regulatory filings regarding the Kratom Consumer Protection Act and adulteration warnings. - U.S. Food and Drug Administration (FDA) – public health advisories on kratom and synthetic opioid contamination. - Centers for Disease Control and Prevention (CDC) – reports on overdose deaths involving kratom and adulterated products. - Drug Enforcement Administration (DEA) – scheduling proposals and public comments on kratom. - Published research in the *Journal of Medical Toxicology* and *Psychopharmacology* on the pharmacology of mitragynine and 7-hydroxymitragynine. - News reports from Reuters, Associated Press, and local outlets covering kratom-related incidents and industry responses.